A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
BZL 101 is an aqueous extract from herba Scutellaria Barbata D. Don of the Lamiaceae family.
Preclinical studies suggest that this herb has antitumor activity for breast cancer and
preliminary clinical data suggest that it is tolerable in patients with metastatic breast
cancer. The overall goals of this Phase I/II trial are to assess the toxicity, maximum
tolerated dose, safety and preliminary efficacy of BZL101 for the treatment of advanced
metastatic breast cancer.